MetaBio Registers Novel Drug Sensitivity Test Method to National Health Insurance

Published: 2005-01-28 06:57:00

Updated: 2005-01-28 06:57:00

MetaBio Co., a domestic biotechnology venture company specialized in cancer treatments and related business, recently announced that the company's drug sensitivity test method for cancer patients has been registered to the National Health Insurance (NHI) list under the non-reimbursement medical service category.

The novel sensitivity test approach is known as 3-D HDRA, which stands for Thre...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.